|Bid||63.45 x 800|
|Ask||63.48 x 1100|
|Day's Range||62.69 - 63.61|
|52 Week Range||57.19 - 74.12|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||17.75|
|Forward Dividend & Yield||2.92 (4.62%)|
|Ex-Dividend Date||Jun 14, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
The FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. The agency has removed the clinical hold after reviewing Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Related: FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.